Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025 Poster presentation at the Society ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

New results from a pooled analysis of patients will be featured in a late-breaking presentation at the upcoming European ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.